Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:approves |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:availableIn |
tablet
injection syrup |
| gptkbp:brand |
Pyribenzamine
Pyrilamine |
| gptkbp:chemicalFormula |
antihistamine
C17H22N2O4S |
| gptkbp:clinicalTrials |
Phase II
Phase III |
| gptkbp:contraindication |
asthma
glaucoma severe liver disease urinary retention prostate enlargement |
| gptkbp:dissolved |
soluble in water
soluble in alcohol |
| gptkbp:enginePower |
9.1
|
| gptkbp:hasFacilities |
350.44 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
pyrilamine maleate
|
| gptkbp:interactsWith |
alcohol
sedatives other antihistamines |
| gptkbp:isATypeOf |
132-20-7
|
| gptkbp:locatedIn |
1950s
|
| gptkbp:operates_in |
R06AB02
|
| gptkbp:origin |
N,N-dimethyl-2-(1-pyrrolidinyl)ethanamine_maleate
|
| gptkbp:relatedPatent |
diphenhydramine
brompheniramine promethazine triprolidine chlorpheniramine |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
dizziness
nausea drowsiness dry mouth blurred vision |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:triggerType |
H1 receptor antagonist
|
| gptkbp:usedFor |
allergy relief
cold symptoms relief hay fever treatment |